Photoangioplasty for human periphoseral atheroscleosis results of a phase I trial of photodynamic therapy with motexafin lutetium (Antrin)

S. G. Rockson, P. Kramer, M. Razavi, A. Szuba, S. Filardo, P. Fitzgerald, John P. Cooke, S. Yousuf, A. R. DeVault, M. F. Renschler, D. C. Adelman

Research output: Contribution to journalArticle

78 Scopus citations

Abstract

Background - In photoangioplasty, light activation of a photosensitive drug offers the potential for treatment of long segments of vascular disease. This is a brief description of a study designed to evaluate the safety and tolerability of a new photosensitizer, Antrin (motexafin lutetium), in the endovascular treatment of atherosclerosis. Methods and Results - An open-label, single-dose, escalating drug- and light-dose study was performed in patients with atherosclerotic peripheral arterial insufficiency. Clinical evaluation, serial quantitative angiography, and intravascular ultrasonography were performed. Therapy was well tolerated, and only minor side effects were observed. Treatment produced no deleterious vascular effects. Although this study was not designed to examine clinical efficacy, several secondary end points suggested a favorable therapeutic effect. Conclusions - This phase I study demonstrates that photoangioplasty with motexafin lutetium is well tolerated and safe. Preliminary efficacy data suggest a future role for the treatment of flow-limiting atherosclerosis.

Original languageEnglish (US)
Pages (from-to)2322-2324
Number of pages3
JournalCirculation
Volume102
Issue number19 SUPPL.
DOIs
StatePublished - Nov 7 2000

Keywords

  • Atherosclerosis
  • Catheters
  • Peripheral vascular disease

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Photoangioplasty for human periphoseral atheroscleosis results of a phase I trial of photodynamic therapy with motexafin lutetium (Antrin)'. Together they form a unique fingerprint.

Cite this